| (2R,3R)-Firazorexton |
|
|
99.85% |
| (R)-YNT-3708 |
|
|
99.07% |
| (R,R)-Suntinorexton |
|
|
99.13% |
| (S)-YNT-3708 |
|
|
99.80% |
| 23ME-00610 |
|
|
|
| [Ala11,D-Leu15]-Orexin B(human) |
|
|
98.31% |
| [Ala11,D-Leu15]-Orexin B(human) TFA |
|
|
|
| ACT-335827 |
|
|
98.0% |
| ACT-462206 |
|
|
99.54% |
| Alixorexton |
|
|
99.96% |
| Alixorexton enantiomer |
|
|
99.42% |
| Almorexant |
|
|
99.96% |
| Almorexant hydrochloride |
|
|
99.98% |
| Almorexant-13C,d3 |
|
|
|
| Amlitelimab (FUT8-KO) |
|
|
|
| Anti-CD200R1/OX2R Antibody (I-4P) |
|
|
|
| Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) |
|
|
|
| Anti-Mouse OX40/CD134 Antibody (OX-86) |
|
|
≥99.0% |
| Anti-Mouse OX40L/CD134L Antibody (RM134L) |
|
|
95.00% |
| Anti-OX2R/CD200R1 Antibody |
|
|
|
| Arvanil |
|
|
99.1% |
| Biotin-DEVD-CHO TFA |
|
|
|
| BTF |
|
|
|
| Cleminorexton |
|
|
|
| Cudarolimab |
|
|
95.00% |
| CVN766 |
|
|
98.31% |
| Danavorexton |
|
|
99.56% |
| DMTr-2'-O-C16-rC(Ac)-3'-CE-phosphoramidite |
|
|
|
| DORA 42 |
|
|
|
| DORA-22 |
|
|
97.67% |
| Efizonerimod alfa |
|
|
98.57% |
| EMPA |
|
|
99.92% |
| Fazamorexant |
|
|
98.95% |
| Filorexant |
|
|
99.40% |
| Firazorexton |
|
|
99.56% |
| Firazorexton hydrate |
|
|
99.94% |
| Fumiporexant |
|
|
|
| GSK1059865 |
|
|
99.68% |
| GYKI-13380 |
|
|
|
| Hypocretin (70-98), human |
|
|
|
| INCAGN1949 |
|
|
|
| IPSU |
|
|
98.0% |
| JNJ-10397049 |
|
|
99.19% |
| JNJ-54717793 |
|
|
98.06% |
| Ledasorexton |
|
|
|
| MEDI-6469 |
|
|
98.3% |
| MK-1064 |
|
|
99.95% |
| MK-3697 |
|
|
98.83% |
| MK-8133 |
|
|
|
| Nivasorexant |
|
|
99.74% |
| Ordastobart |
|
|
98% |
| Orexin 2 Receptor Agonist |
|
|
99.59% |
| Orexin 2 Receptor Agonist 2 |
|
|
98.06% |
| Orexin 2 Receptor Agonist 3 |
|
|
|
| Orexin A (16-33) |
|
|
|
| Orexin A (human, rat, mouse) |
|
|
99.58% |
| Orexin A (human, rat, mouse) acetate |
|
|
99.53% |
| Orexin A (human, rat, mouse) TFA |
|
|
98.13% |
| Orexin A-13C18,15N3 (human, rat, mouse) TFA |
|
|
98.60% |
| Orexin A-13C5,15N (human, rat, mouse) TFA |
|
|
|
| Orexin B, human |
|
|
|
| Orexin B, human acetate |
|
|
99.68% |
| Orexin B, human TFA |
|
|
99.46% |
| Orexin B, human-13C18,15N3 TFA |
|
|
96.88% |
| Orexin B, human-13C6,15N TFA |
|
|
|
| Orexin B, rat, mouse |
|
|
99.66% |
| Orexin B, rat, mouse TFA |
|
|
98.68% |
| Orexin receptor activator-1 |
|
|
|
| Orexin receptor antagonist 2 |
|
|
98.08% |
| Orexin receptor antagonist 3 |
|
|
99.62% |
| Orexin receptor antagonist 4 |
|
|
|
| Orexin receptor antagonist 6 |
|
|
|
| Orexin receptor antagonist 7 |
|
|
|
| Orexin receptor modulator-1 |
|
|
|
| Oveporexton |
|
|
99.68% |
| OX-201 |
|
|
|
| OX2-2303 |
|
|
|
| OX2R agonist 1 |
|
|
|
| OX2R agonist 3 |
|
|
|
| OX2R-IN-1 |
|
|
|
| OX2R-IN-3 |
|
|
|
| OXA(17-33) |
|
|
97.48% |
| OXA(17-33) TFA |
|
|
|
| Revdofilimab |
|
|
99.35% |
| Rocavorexant |
|
|
|
| RTIOXA-43 |
|
|
99.94% |
| SB-334867 |
|
|
99.08% |
| SB-334867 free base |
|
|
99.88% |
| SB-408124 |
|
|
98.93% |
| SB-408124 Hydrochloride |
|
|
98.79% |
| SB-649868 |
|
|
99.45% |
| SB-674042 |
|
|
99.87% |
| Seltorexant |
|
|
99.83% |
| Seltorexant hydrochloride |
|
|
99.90% |
| SHR-1806 |
|
|
|
| Solaprubart |
|
|
99.59% |
| Suntinorexton |
|
|
98.66% |
| TCS 1102 |
|
|
99.73% |
| TCS-OX2-29 |
|
|
99.17% |
| TCS-OX2-29 hydrochloride |
|
|
|
| Tebideutorexant |
|
|
98.95% |
| Vedastotug |
|
|
99.66% |
| Vornorexant |
|
|
98.41% |
| Xenopus orexin A |
|
|
|
| Xenopus orexin B |
|
|
|
| YNT-185 |
|
|
98.46% |
| YNT-185 dihydrochloride |
|
|
99.78% |
| YNT-3708 |
|
|
|
| ZL-1101 |
|
|
|
| Vonlerolizumab |
|
|
99.70% |
| Valerosidate |
|
|
|
| Rocatinlimab |
|
|
99.95% |